Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Gapping up/down: PVH +7%, FIVE +7% and CEO +1% after earnings, FEYE +8% after upgrades at GS; CHL -3%, ACN -3%, and CAG -2% after earnings, DG and MO -1% after dg's<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>TAT</strong> +9.6%, <strong>CGIX</strong> +8.6%, <strong>CMC</strong> +8.3%, <strong>PVH</strong> +7.3%, <strong>FIVE</strong> +6.7%, <strong>MLHR</strong> +5.6% <strong>APOP</strong> +4.4%, <strong>PIRS</strong> +2%, <strong>CUR</strong> +1.9%, <strong>CEO</strong> +1.4%, <strong>NEOT</strong> +1.4%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>ZNH</strong> +1.1% (issues statement, says it requested the halt pending the release of an announcement in relation to the possible major strategic cooperation which is the inside information of the Company)</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>HTGM</strong> +56.5% (obtains CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU)</li><li><strong>DRWI</strong> +29.3% (announced the selection of the Harmony Enhanced MC backhaul solution by Corridor Communication )</li><li><strong>SSH</strong> +20.6% (highlights 'progress in successfully executing its Aquadex growth strategy')</li><li><strong>BEBE</strong> +7.5% ( says exploring strategic alternatives)</li><li><strong>DHT</strong> +6% (acquires 11 VLCCs from BW Group for $538 mln; will issue $256 million of DHT capital stock)</li><li><strong>INSY</strong> +5.8% (DEA has issued an interim final rule that would result in Syndros being placed in Schedule II of the Controlled Substances Act; anticipates finalizing the labeling and subsequent launch of Syndros in the second half of 2017)</li><li><strong>EGLT</strong> +5.6% (announces the issuance of new U.S. and international patents for its proprietary Guardian Technology)</li><li><strong>PRKR</strong> +4.8% ( seeing continued strength in afterhours — confirms will report financial results on Thursday, March 30, 2017 with call at 4:30 p.m. Eastern time)</li><li><strong>PENN</strong> +4.4% (will replace Cynosure in the S&P SmallCap 600)</li><li><strong>LJPC</strong> +1.9% (prices an underwritten public offering of approx 3.7 mln shares of common stock at $33.50/share for gross proceeds of $125 mln)</li><li><strong>CPB</strong> +1% (announces $1.5 bln share repurchase program)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>FEYE</strong> +8.4% (upgraded to Buy from Sell at Goldman)</li><li><strong>SVU</strong> +6.9% (upgraded to Outperform at RBC Capital Mkts)</li><li><strong>RACE</strong> +2.3% (upgraded to Buy from Neutral at Citigroup)</li><li><strong>CHK</strong> +2% (initiated with Buy at Stifel )</li><li><strong>KR</strong> +1.7% (upgraded to Outperform at RBC Capital Mkts)</li><li><strong>BABA</strong> +0.9% (initiated with Overweight ratings at Pacific Crest)</li><li><strong>JD</strong> +0.9% (initiated with Overweight ratings at Pacific Crest)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>CHL</strong> -2.7%, <strong>ACN</strong> -2.6%, <strong>KDMN</strong> -2.4%, <strong>CAG</strong> -1.9%, <strong>ASND</strong> -1.5%, <strong>BGNE</strong> -0.6%, <strong>EHIC</strong> -0.5%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>TNDM</strong> -22.6% (prices offering of 18 mln shares at $1.25/share)</li><li><strong>HTBX</strong> -20.4% (prices underwritten public offering of 5 mln shares of its common stock at $0.80/share)</li><li><strong>QUIK</strong> -12.2% (prices 10 mln common stock offering at $1.50/share)</li><li><strong>OEC</strong> -8.3% (announces that Kinove Luxembourg Holdings and certain other sellers intend to offer an aggregate of 5 mln common shares in an underwritten public offering)</li><li><strong>RARE</strong> -6.9% (announces topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome patients with seizures; study did not meet the primary endpoint)</li><li><strong>VNCE</strong> -5.3% (following late move higher)</li><li><strong>BLCM</strong> -4.3% (commences an underwritten public offering of 5,000,000 shares of its common stock)</li><li><strong>SHLD</strong> -3.9% (continued weakness)</li><li><strong>CHMI</strong> -3.8% (commences 4.5 mln common stock offering)</li><li><strong>ENPH</strong> -3.2% (files for approx 12 mln share common stock offering by selling shareholder)</li><li><strong>MMSI</strong> -3% (prices offering of 4.5 mln shares of common stock at $28.25 per share)</li><li><strong>KEYS</strong> -1.6% (offering of 11,428,571 common shares at $35.00 per share)</li><li><strong>MYL</strong> -0.9% ( indicated lower in after hours on EpiPen recall news)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>WLL</strong> -1.7% (downgraded to Sell from Neutral at UBS)</li><li><strong>GPOR</strong> -1.6% (downgraded to Neutral from Buy at Goldman)</li><li><strong>DG</strong> -1.2% (downgraded to Underperform from Neutral at Credit Suisse)</li><li><strong>NSC</strong> -1.1% (downgraded to Underperform at RBC Capital Mkts)</li><li><strong>MO</strong> -1.1% (downgraded to Underperform at RBC Capital Mkts)</li><li><strong>PEGI</strong> -1% (downgraded to Neutral from Outperform at Macquarie)</li></ul></td> </tr></table>"